Institute of Infectious Diseases and Tropical Medicine
  1. Homepage LMU Hospital
  2. Tropical Institute
  3. Research
  4. Co-vaccination study

Co-vaccination study for COVID-19 vaccinated people

The aim of the CoCoVaccine study is to better understand the short-, medium- and long-term serological immune response in SARS-CoV-2 vaccinated individuals. To this end, over 6,000 participants were included in the study, mainly healthcare professionals who had each received at least one vaccination against COVID-19.

The research interest lay in the following questions: Do you know your SARS-CoV-2 antibody status? With which antibody constellations do COVID-19 infections and illnesses occur? From what titer are you protected? Are asymptomatic infections possible after vaccination, which can be passed on to people in the vicinity despite (or precisely because of) the lack of signs of illness? What does the presumed correlation between antibody titres and disease risk or disease severity shown in the diagram actually look like? And, of course, the most important question of all:

In what range are your antibodies today?

By participating in the KoCo vaccination study, you will not only receive a snapshot; we will determine your antibodies over the long term and put the values into a form that you can understand. Our aim is for us to be able to work together to create a reliable, individual basis for deciding on your personal infection protection and the timing of any necessary COVID-19 vaccination booster.

Data for action - our questions in detail

  • With which antibody constellations do COVID-19 infections and diseases occur?
  • From what titer are you protected?
  • In which range are your antibodies today and in the further course?

Contact for participants

Please note that the telephone study hotline for the KoCo vaccination study is no longer active.

You can still reach us by e-mail:
KoCo19@med.uni-muenchen.de

Your advantages at a glance

  • SARS-CoV-2 antibodies over time: once is not always enough. Although a single analysis of SARS-CoV-2 antibodies already allows initial conclusions to be drawn about the probability of immune protection, you can gain more reliable insights into the course of your body's immune response after COVID-19 vaccination by repeatedly determining different antibody types over a period of several months.
  • Comparison of SARS-CoV-2 antibodies: The comparison of your individual antibody titers over time is supplemented by a classification of these immunological parameters in the totality of the results of all participants in the KoCo vaccination study and - wherever possible - in the findings of a growing number of international studies in this field. In other words, we expect to fill in the hypothetical diagram on the cover of this brochure with real data as the study progresses. This would allow you to assess whether your current values are in the green, yellow or red zone.
  • Recognize silent infections: The antibody response after vaccination is fundamentally different from the immune response after infection with the virus. By regularly determining relevant immune markers, we can determine whether you have been infected with one of the SARS-CoV-2 variants despite vaccination and possibly without developing signs of illness. As in most cases this will only take place some time after such an infection, we also offer you the option of having a PCR smear test carried out at the Tropical Institute on weekdays.

About the study and information for participants

Study results

Understanding the Omicron Variant Impact in Healthcare Workers: Insights from the Prospective COVID-19 Post-Immunization Serological Cohort in Munich (KoCo-Impf) on Risk Factors for Breakthrough and Reinfections.
Janke C, Rubio-Acero R, Weigert M, Reinkemeyer C, Khazaei Y, Kleinlein L, Le Gleut R, Radon K, Hannes M, Picasso F, et al.
Viruses. 2024; 16(10):1556.

The Prospective COVID-19 Post-Immunization Serological Cohort in Munich (KoCo-Impf): Risk Factors and Determinants of Immune Response in Healthcare Workers.
Reinkemeyer C, Khazaei Y, Weigert M, Hannes M, Le Gleut R, Plank M, Winter S, Noreña I, Meier T, Xu L, et al.
Viruses. 2023; 15(7):1574.

Study cooperations

The project is also funded by the pan-European consortium ORCHESTRA. The ORCHESTRA project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 101016167. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein.